Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Beam Therapeutics Inc BEAM

Healthcare Biotechnology
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver... see more

Current News (NDAQ:BEAM)

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

GlobeNewswire 3 days ago

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

GlobeNewswire 4 days ago

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

GlobeNewswire 9 days ago

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

GlobeNewswire April 1, 2026

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

GlobeNewswire March 25, 2026

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

GlobeNewswire February 24, 2026

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

GlobeNewswire February 24, 2026

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

GlobeNewswire February 23, 2026

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

GlobeNewswire January 11, 2026
View More News ››

Opinion & Analysis (NDAQ:BEAM)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BEAM)

Buy buddy buy because it's taking off this morning.

Otherwise it will be FOMO time for you fellas out there today anyway
coolfooldumbguy - January 12, 2026

Using technical analysis for this stock.

After making a head and shoulders formation recently this stock is a good BUY for me
coolfooldumbguy - September 3, 2025
View more Bullboard ››

NU E Power Corp.

NU E Power Corp.

NU E Power Corp. is an energy infrastructure company focused on the origination, development, and advancement of integrated ...
View More »

Podcasts